Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Toxicogenomic Project Aims at Safety Prediction System
May 13, 2002
- REGULATORY NEWS IN BRIEF
May 13, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 13, 2002
- Kenporen, JMA Share Opinions on Review of Medical Fees
May 13, 2002
- 6 New Switch OTC Drugs Recommended for Approval
May 13, 2002
- Specialist System for Surgeons to Begin from June
May 13, 2002
- OTC NEWS IN BRIEF
May 13, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 13, 2002
- WORLD NEWS IN BRIEF
May 13, 2002
- Applicants' Sales Forecasts for New Drugs Announced by Korosho
April 29, 2002
- MEDICAL DEVICE NEWS IN BRIEF
April 29, 2002
- Korosho Invites Opinions on Its Vision from Industry
April 29, 2002
- Becton Dickinson Proposes Safe, Efficient Lab Testing Centers
April 29, 2002
- BULLETIN
April 29, 2002
- Eli Lilly Asked to Distribute Dear-Doctor Letter on Zyprexa
April 29, 2002
- Sysmex: New Blood Cell Analyzer XT-2000i
April 29, 2002
- Competition Intensifies on Market for Antidepressants
April 29, 2002
- Companies' Responsibility for Promotion of Medical Safety Clarified
April 29, 2002
- We Are Open to Strategic Alliance: Mr Wright of AstraZeneca
April 29, 2002
- Eisai to Apply for Vascular Dementia for Aricept in US
April 29, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…